MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Menarini, focused on making a difference
For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions. At Menarini we understand that patients’ hope for a better life is inextricably linked to the persistence and progress of our researchers – that is what drives us forward.
With 9 research centers across Europe, the US and Southeast Asia, MENARINI R&D develops projects from the preclinical phase to drug registration.
Our Approach to R&D
Our R&D division is focused on developing innovation in life sciences to improve the health of patients. In collaboration with our Business Development & Licensing and Marketing teams, we identify the most promising opportunities and apply our expertise in drug development to transform them into high-quality medicines that will improve patients’ lives.
Continued investments in technology and in enhancing the skills and knowledge of our researchers means that we can deliver scientific breakthroughs and meaningfully contribute to finding cures for difficult-to-treat diseases.

Our research areas
We are strengthening our pipeline with a focus on science related to oncology and infectious diseases, two areas where we are well positioned to develop innovative therapies and to bring to patients in need.

Our pipeline and products
Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.
Clinical trials
The Menarini Group is committed to enhancing public health trough responsible sharing of clinical trial data.
